SAN DIEGO, CA and CALGARY, AB, Nov. 3, 2023 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC.TO), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of a poster that provides further positive translational data from the previously completed AWARE-1 breast cancer window-of-opportunity study, sponsored by SOLTI-Innovative Cancer Research, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.
Read more at newswire.caOncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC
Newswire.ca -
Fri Nov 3, 2023
Columnist
Contributor Content
Press Release
Sponsored Content
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Tesla%20Inc%20logo%20by-%20baileystock%20via%20iStock(1).jpg)
